Blog
About

2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Successful Treatment of Hyponatremia with Angiotensin-Converting Enzyme Inhibitors in Patients with Congestive Heart Failure

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hyponatremia commonly complicates the clinical course of patients with congestive heart failure (CHF) and seems to be an ominous prognostic factor. Angiotensin-converting enzyme (ACE) inhibitors improve the symptomatology of CHF patients. Moreover, it has been reported that these drugs can raise serum sodium in hyponatremic patients. The aim of this prospective work was to study the mechanisms involved in the correction of hyponatremia in 6 patients aged 52-69 years with CHF and hyponatremia (serum sodium 125– 128 mmol/l) who were receiving digitalis and furosemide. In these patients, captopril was introduced in progressively increasing doses. The drug induced significant clinical improvement. Additionally, a statistically significant increase in serum sodium was observed which was correlated to a rise in the diluting ability of the kidney (increase in C<sup>e</sup>H<sub>2</sub>O). A slight increase in creatinine clearance was also found, which could have contributed to the improvement in hyponatremia. Therefore, we conclude that ACE inhibitors can improve hyponatremia in CHF patients by increasing the urinary diluting ability.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1995
          1995
          19 November 2008
          : 86
          : 6
          : 477-480
          Affiliations
          Department of Internal Medicine, University of Ioannina, Greece
          Article
          176926 Cardiology 1995;86:477–480
          10.1159/000176926
          7585758
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Clinical Pharmacology

          Comments

          Comment on this article